New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
07:31 EDTFOLDAmicus Theraputics weakness a buying opportunity, says JPMorgan
JPMorgan views the pullback in shares of Amicus Theraputics on the company's Phase 3 trial miss as a buying opportunity. The firm says migalastat is active in Fabry and safe, and reiterates an Overweight rating on the stock, despite lowering its price target for shares to $5 from $9.
News For FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
14:10 EDTFOLDGlaxoSmithKline liquidates passive stake in Amicus Therapeutics
Subscribe for More Information
09:37 EDTFOLDActive equity options trading
Subscribe for More Information
08:59 EDTFOLDAmicus Therapeutics 11.32M share Block Trade priced at $5.40
Subscribe for More Information
October 20, 2014
07:10 EDTFOLDAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 19, 2014
19:46 EDTFOLDAmicus announces additional positive data from from Fabry monotherapy study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use